EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion

Katherine Reifler iD, Alyse Wheelock, Samantha M Hall, Madolyn Dauphinais, Samuel Roytburd, Michael Maiullari, Alejandra Salazar, Ashley Maldonado, Helen Mahoney West, Julia R Köhler, Elizabeth D Barnett, Deepa M Gopal und 2 weitere

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Katherine Reifler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Infectious Disease, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United Stat…. Hauptthemen laut MEDLINE: Chagas Disease, Trypanocidal Agents, Nitroimidazoles, Nifurtimox. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Office of AIDS Research, Centers for Disease Control and Prevention Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-trypanosomal therapy is generally recommended for individuals under age 50 with the indeterminate form of Chagas disease to prevent disease progression. However, benznidazole and nifurtimox are associated with adverse drug reactions. We performed a retrospective review of treatment tolerability among patients with Chagas disease referred to Boston Medical Center from June 2016 to June 2024. There were 125 individuals evaluated, of whom 32 (25.6%) had contraindications to and 2 (1.6%) declined antiparasitic treatment. Ninety-one started therapy (83 with benznidazole, 8 with nifurtimox) with monitoring co-managed by infectious diseases physicians and pharmacists. Following benznidazole initiation, 70 (84.3%) had at least one adverse event, of which allergic (39/83, 47.0%), gastrointestinal (38/83, 45.8%), and neuropsychiatric (33/83, 39.8%) reactions were most common. Rash led to treatment discontinuation in 19 patients (22.9%) and met criteria for grade 3 severity in 13 (15.7%). Adjunctive therapies for rash included topical and systemic steroids and systemic antihistamines. Peripheral neuropathy led to treatment cessation for 13 patients (15.7%). Gastrointestinal adverse effects occurred in 38 patients (45.8%), were relatively mild, and managed with H2 blockers or proton pump inhibitors. Thirty (36.1%) patients were unable to complete 60 days of benznidazole, of whom 15 switched to nifurtimox. Eight patients started with nifurtimox during a benznidazole shortage. Nifurtimox was more frequently associated with gastrointestinal side effects (21/23, 91.3%) compared to benznidazole. Ultimately, 83 patients (91.2%) received at least 30 days, and 68 patients (74.7%) completed at least 60 days of benznidazole or nifurtimox. Multiple strategies were used to prevent and alleviate adverse events; multi-disciplinary team management was essential. These findings underscore the support needed for individuals with Chagas disease to tolerate and complete therapy and highlight the need for safer and more effective options to facilitate access to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chagas DiseaseTrypanocidal AgentsNitroimidazolesNifurtimoxDrug-Related Side Effects and Adverse ReactionsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultAgedYoung Adult

Substanzen

Trypanocidal AgentsNitroimidazolesNifurtimoxbenzonidazole

Autor:innen und Institutionen

  • Section of Infectious Disease, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
  • Section of Preventative Medicine and Epidemiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
  • Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.
  • Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, United States of America.
  • Division of Infectious Disease, Boston Children's Hospital, Boston, Massachusetts, United States of America.
  • Harvard Medical School, Boston, Massachusetts, United States of America.

ORCID-Profile: Katherine Reifler

Förderung

  • NIAID NIH HHS
  • Office of AIDS Research
  • Centers for Disease Control and Prevention Foundation

Zitieren

APA

Reifler, K., Wheelock, A., Hall, S. M., Dauphinais, M., Roytburd, S., Maiullari, M., Salazar, A., Maldonado, A., West, H. M., Köhler, J. R., Barnett, E. D., Gopal, D. M., Hamer, D. H., & Bourque, D. L. (2025). Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013218

Vancouver

Reifler K, Wheelock A, Hall SM, Dauphinais M, Roytburd S, Maiullari M, et al. Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013218

BibTeX
@article{Reifler2025,
  author = {Reifler, Katherine and Wheelock, Alyse and Hall, Samantha M and Dauphinais, Madolyn and Roytburd, Samuel and Maiullari, Michael and Salazar, Alejandra and Maldonado, Ashley and West, Helen Mahoney and Köhler, Julia R and Barnett, Elizabeth D and Gopal, Deepa M and Hamer, Davidson H and Bourque, Daniel L},
  title = {Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013218}
}
Kostenlos starten →